Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
50 hedge funds and large institutions have $58M invested in Concert Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 13 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
4% more funds holding
Funds holding: 48 → 50 (+2)
26% less capital invested
Capital invested by funds: $78.7M → $58M (-$20.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$3.85M |
| 2 |
Principal Financial Group
Des Moines,
Iowa
|
+$1.21M |
| 3 |
BG
BlackRock Group
London,
United Kingdom
|
+$964K |
| 4 |
Bank of New York Mellon
New York
|
+$534K |
| 5 |
Citigroup
New York
|
+$533K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$3.06M |
| 2 |
BC
Broadfin Capital
New York
|
-$2.69M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.57M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.34M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$807K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
51
JP Morgan Chase
New York
| – | -$3.06M | -227,250 | Closed |
|
|
BC
52
Broadfin Capital
New York
| – | -$2.69M | -200,000 | Closed |
|
|
53
Marshall Wace
London,
United Kingdom
| – | -$807K | -60,000 | Closed |
|
|
RSCM
54
Rock Springs Capital Management
Baltimore,
Maryland
| – | -$801K | -59,553 | Closed |
|
|
FCM
55
Farallon Capital Management
San Francisco,
California
| – | -$790K | -58,700 | Closed |
|
56
State Street
Boston,
Massachusetts
| – | -$590K | -43,859 | Closed |
|
|
JC
57
JBF Capital
Aspen,
Colorado
| – | -$559K | -41,556 | Closed |
|
|
SCA
58
SAC Capital Advisors
Stamford,
Connecticut
| – | -$432K | -32,118 | Closed |
|
|
NFA
59
Nationwide Fund Advisors
Columbus,
Ohio
| – | -$198K | -14,746 | Closed |
|
|
CS
60
Credit Suisse
Zurich,
Switzerland
| – | -$174K | -12,910 | Closed |
|
61
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| – | -$163K | -12,100 | Closed |
|
|
TA
62
Teachers Advisors
New York
| – | -$91K | -6,750 | Closed |
|
|
SSG
63
Summit Securities Group
New York
| – | -$13K | -1,000 | Closed |
|
CNCE Hedge Fund Activity: Q2 2014 in Review
50 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q2 2014, worth a combined $58M — down 26% from $78.7M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CNCE positions and 13 closed out — a net gain of 2 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $3.85M. The largest seller was JP Morgan Chase, exiting entirely with an estimated $3.06M sold.
- 50 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q2 2014, up from 48 in Q1 2014.
- Funds reported $58M of Concert Pharmaceuticals, Inc. stock for Q2 2014, down 26% quarter-over-quarter.
- 15 funds opened new Concert Pharmaceuticals, Inc. positions in Q2 2014 and 13 closed out, a net change of +2 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q2 2014 was Baker Bros. Advisors, an estimated $3.85M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q2 2014 was JP Morgan Chase, an estimated $3.06M sold.
Based on aggregated 13F filings for Q2 2014.